{"transactions":[{"id":730502,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:12:26.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":34000,"derivative":{"exercise_price":1.79,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001835597-26-000033","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690959/000183559726000033/form4.xml","form_type":"4"}},{"id":732423,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-18T21:37:26.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":17340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), the RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), the RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":17340,"derivative":{"exercise_price":36.73,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":17340},"source":{"system":"sec-edgar","filing":"0001690959-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000169095926000004/edgardoc.xml","form_type":"4"}},{"id":944527,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:20:45.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5079,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":21.31,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":5079},"source":{"system":"sec-edgar","filing":"0001690959-26-000002","document":"wk-form4_1767835242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690959/000169095926000002/wk-form4_1767835242.xml","form_type":"4"}},{"id":944526,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:20:45.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":26.62,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":22200},"source":{"system":"sec-edgar","filing":"0001690959-26-000002","document":"wk-form4_1767835242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690959/000169095926000002/wk-form4_1767835242.xml","form_type":"4"}},{"id":1106333,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T21:09:43.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":5079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual director stock option grant of 11,100 shares is pro-rated based on the number of days served on the Issuer's board of directors prior to the grant date divided by 365 days."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall vest on the earlier of (i) June 18, 2026 or (ii) the day prior to the date of the Issuer's 2026 annual meeting of stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":5079,"derivative":{"exercise_price":21.31,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":5079},"source":{"system":"sec-edgar","filing":"0001610618-25-000069","document":"wk-form4_1750280976.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690959/000161061825000069/wk-form4_1750280976.xml","form_type":"4"}},{"id":1110093,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-16T21:07:30.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":19959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), the RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), the RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in full upon the earlier of June 12, 2026 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":19959,"derivative":{"exercise_price":16.99,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":19959},"source":{"system":"sec-edgar","filing":"0002036042-25-000030","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000203604225000030/edgardoc.xml","form_type":"4"}},{"id":1119687,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T10:47:21.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"his option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.\""}],"balance_after":16000,"derivative":{"exercise_price":1.51,"exercise_date":"2026-06-04","expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001127602-25-016927","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690959/000112760225016927/form4.xml","form_type":"4"}},{"id":1135499,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T21:45:40.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject\nto the Reporting Person's continued service as a director through such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"). The Reporting Person is obligated to turn over to\nthe Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":30000,"derivative":{"exercise_price":0.1868,"expiration_date":"2035-05-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-014533","document":"form4-05232025_090536.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925014533/form4-05232025_090536.xml","form_type":"4"}},{"id":1308087,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T23:38:27.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":22200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the total number of shares subject to the award shall vest on January 3, 2026 and the remaining 2/3rds of the shares will vest in equal monthly installments over the following two year period such that the option is fully vested on January 3, 2028."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":22200,"derivative":{"exercise_price":26.62,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":22200},"source":{"system":"sec-edgar","filing":"0001610618-25-000006","document":"wk-form4_1736293101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690959/000161061825000006/wk-form4_1736293101.xml","form_type":"4"}},{"id":1472085,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T20:09:53.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), the RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":13000,"derivative":{"exercise_price":16.8,"exercise_date":"2025-06-20","expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001127602-24-019121","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690959/000112760224019121/form4.xml","form_type":"4"}},{"id":1486977,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T22:00:16.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 5, 2025 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":18.9,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-016057","document":"form4-06072024_060612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000141588924016057/form4-06072024_060612.xml","form_type":"4"}},{"id":1500559,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-28T20:10:12.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 23, 2025 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject\nto the Reporting Person's continued service as a director through such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"). The Reporting Person is obligated to turn over to\nthe Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-24-014646","document":"form4-05282024_040508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924014646/form4-05282024_040508.xml","form_type":"4"}},{"id":1844238,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T20:14:57.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."}],"balance_after":12000,"derivative":{"exercise_price":9.61,"exercise_date":"2024-06-22","expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001127602-23-019409","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690959/000112760223019409/form4.xml","form_type":"4"}},{"id":1862517,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-08T22:00:23.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 6, 2024 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":12500,"derivative":{"exercise_price":16.3,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-23-009444","document":"form4-06082023_060606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000141588923009444/form4-06082023_060606.xml","form_type":"4"}},{"id":1870203,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:39:52.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 26, 2024 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":30000,"derivative":{"exercise_price":4.79,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-033824","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000120919123033824/doc4.xml","form_type":"4"}},{"id":2224228,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T21:00:57.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 21, 2023 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":12500,"derivative":{"exercise_price":12.26,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-22-017507","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000149315222017507/ownership.xml","form_type":"4"}},{"id":2230137,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-16T21:12:45.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":16911,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":16911,"derivative":{"exercise_price":4.26,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":16911},"source":{"system":"sec-edgar","filing":"0001209191-22-037522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000120919122037522/doc4.xml","form_type":"4"}},{"id":2276204,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-10T22:54:04.000Z","date":"2022-05-06","kind":"grant","acquired":true,"shares":11667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.\""}],"balance_after":11667,"derivative":{"exercise_price":12,"expiration_date":"2032-05-05","underlying":"Common Stock","underlying_shares":11667},"source":{"system":"sec-edgar","filing":"0000899243-22-017502","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690959/000089924322017502/doc4.xml","form_type":"4"}},{"id":2647911,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-01T22:36:50.000Z","date":"2021-06-29","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in 36 substantially equal monthly installments, with the first installment vesting on July 29, 2021."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund, L.P. (the \"Nexus Fund\").  The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and Nexus Fund to the Adviser.  The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":25000,"derivative":{"exercise_price":14,"expiration_date":"2031-06-28","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-21-088387","document":"tm2121189-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000110465921088387/tm2121189-9_4seq1.xml","form_type":"4"}},{"id":2872357,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-09T22:17:24.000Z","date":"2021-02-05","kind":"grant","acquired":true,"shares":16900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares underlying the option vest in equal monthly installments commencing on March 5, 2021, provided that the Reporting Person remains continuously engaged by the Issuer on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund, the Nexus Fund and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":16900,"derivative":{"exercise_price":18,"expiration_date":"2031-02-04","underlying":"Common Stock","underlying_shares":16900},"source":{"system":"sec-edgar","filing":"0001209191-21-008893","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000120919121008893/doc4.xml","form_type":"4"}},{"id":4199168,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-09-30T00:17:42.000Z","date":"2017-09-27","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 12 month period: 1/12th on October 27, 2017, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The option is held by the reporting person for the benefit of SV Health Investors, LLC.  The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":6000,"derivative":{"exercise_price":6.71,"expiration_date":"2027-09-26","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001140361-17-037024","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690959/000114036117037024/doc1.xml","form_type":"4"}},{"id":4371625,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-03-27T23:08:16.000Z","date":"2017-03-23","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The option is held by the reporting person for the benefit of SV Life Sciences Advisers, LLC.  The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 3 year period: 1/36th on December 21, 2016, after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The option is held by the reporting person for the benefit of SV Life Sciences Advisers, LLC.  The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The option is held by the reporting person for the benefit of SV Life Sciences Advisers, LLC.  The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":12000,"derivative":{"exercise_price":7.88,"expiration_date":"2027-03-22","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001140361-17-013500","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690959/000114036117013500/doc1.xml","form_type":"4"}},{"id":4540210,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-11-30T01:07:49.000Z","date":"2016-11-21","kind":"grant","acquired":true,"shares":71211,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund IV Strategic Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 191,091 shares of KalVista Pharmaceuticals, Ltd. Series A Preferred Shares and 53,523 shares of Series B Preferred Shares in connection with the closing of the Transaction. On the effective date of the Transaction, the closing price of the Company's common stock was $9.38 per share. All numbers give effect to the Reverse Stock Split. Prior to the Reverse Stock Split, the closing price of the Company's common stock was $0.67 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"SV Life Sciences Fund IV Strategic Partners, L.P., a Delaware limited partnership, and (ii)  SV Life Sciences Fund IV, L.P., a Delaware limited partnership. The general partner of both SV Life Sciences Fund IV, L.P. and SV Life Sciences Fund IV Strategic Partners, L.P. (collectively, the \"Funds\") is SV Life Sciences Fund IV (GP), L.P. The general partner of SV Life Sciences Fund IV (GP), L.P. is SVLSF IV, LLC. Both SV Life Sciences Fund IV (GP), L.P. and SVLS IV, LLC may be deemed to beneficially own the shares held by the Funds. SV Life Sciences Fund IV (GP), L.P. and SVLS IV, LLC may be deemed to beneficially own the shares held by the Funds. SV Life Sciences Fund IV (GP), L.P. and SVLS IV, LLC disclaim beneficial ownership of the shares held by the Funds except to the extent of any pecuniary interest therein. Dr. Resnick, a director of Issuer, is a partner of SV Life Sciences."}],"balance_after":71211,"source":{"system":"sec-edgar","filing":"0001140361-16-088115","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690959/000114036116088115/doc1.xml","form_type":"4"}},{"id":4540209,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":36337,"kind":"person","name":"Resnick Joshua","position":1,"cik":"0001690959","reported_name":"Resnick Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-11-30T01:07:49.000Z","date":"2016-11-21","kind":"grant","acquired":true,"shares":2508279,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 6,730,810 shares of KalVista Pharmaceuticals, Ltd. Series A Preferred Shares and 1,885,228 shares of Series B Preferred Shares in connection with the closing of the share purchase transaction (the \"Transaction\") whereby KalVista Pharmaceuticals, Ltd. became a wholly-owned subsidiary of Carbylan Therapeutics, Inc., which changed its name to KalVista Pharmaceuticals, Inc. (the \"Company\"). On the effective date of the Transaction, the closing price of the Company's common stock was $9.38 per share. All numbers give effect to the 14:1 reverse stock split effected by the Company on November 21, 2016 (the \"Reverse Stock Split\"). Prior to the Reverse Stock Split, the closing price of the Company's common stock was $0.67 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"SV Life Sciences Fund IV Strategic Partners, L.P., a Delaware limited partnership, and (ii)  SV Life Sciences Fund IV, L.P., a Delaware limited partnership. The general partner of both SV Life Sciences Fund IV, L.P. and SV Life Sciences Fund IV Strategic Partners, L.P. (collectively, the \"Funds\") is SV Life Sciences Fund IV (GP), L.P. The general partner of SV Life Sciences Fund IV (GP), L.P. is SVLSF IV, LLC. Both SV Life Sciences Fund IV (GP), L.P. and SVLS IV, LLC may be deemed to beneficially own the shares held by the Funds. SV Life Sciences Fund IV (GP), L.P. and SVLS IV, LLC may be deemed to beneficially own the shares held by the Funds. SV Life Sciences Fund IV (GP), L.P. and SVLS IV, LLC disclaim beneficial ownership of the shares held by the Funds except to the extent of any pecuniary interest therein. Dr. Resnick, a director of Issuer, is a partner of SV Life Sciences."}],"balance_after":2508279,"source":{"system":"sec-edgar","filing":"0001140361-16-088115","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690959/000114036116088115/doc1.xml","form_type":"4"}}]}